TScan Therapeutics (TCRX) Net Cash Flow (QoQ) (2020 - 2026)
TScan Therapeutics (TCRX) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | TScan Therapeutics | 100.19 Mn | -27.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.39% |
| Dec 31, 2025 | -15,367.86% |
| Sep 30, 2025 | -99.27% |
| Jun 30, 2025 | 162.19% |
| Mar 31, 2025 | -153.94% |
| Dec 31, 2024 | 141.79% |
| Sep 30, 2024 | -207.28% |
| Jun 30, 2024 | 1,320.83% |
| Mar 31, 2024 | 132.77% |
| Dec 31, 2023 | 59.30% |
| Sep 30, 2023 | -139.06% |
| Jun 30, 2023 | 8.12% |
| Mar 31, 2023 | -41.36% |
| Dec 31, 2022 | -247.65% |
| Sep 30, 2022 | 176.85% |
| Jun 30, 2022 | 25.95% |
| Mar 31, 2022 | -24.87% |
| Dec 31, 2021 | -121.64% |
| Sep 30, 2021 | 597.35% |
| Jun 30, 2021 | -117.65% |